NCT06607796

Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

A Multicenter Study of the Efficacy and Safety of Intratumoral Injection of Toluenesulfonamide (PTS) in Combination With or Without First-line Chemoimmunotherapy Based on Standard Treatment for Stage IV Driver Gene-negative Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Zhou Chengzhi · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study was to evaluate the efficacy and safety of intratumoral injection of toluenesulfonamide(PTS) in combination with or without first-line chemoimmunization based on standard treatment for stage IV driver gene-negative non-small cell lung cancer.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Toluenesulfonamide (PTS) Intratumoral Injection	intratumoral injection of toluenesulfonamide(PTS) to oligo lesions

Timeline

• Start date: 2024-03-01
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2024-09-23
• Last updated: 2024-09-25

Locations

1 site across 1 country: China